Disease · MONDO_0005296

sleep apnea syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. sleep apnea syndrome. Diseases, record MONDO_0005296. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005296

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: sleep apnea syndrome; Open Targets
Open Targets ID: MONDO_0005296; Open Targets
Other names: Apnea Syndrome, Sleep, Apnea Syndromes, Sleep, Apnea, Sleep, Apneas, Sleep, Breathing, Sleep-Disordered, Hypersomnia with Periodic Respiration, Hypopnea, Sleep, Hypopneas, Sleep, Mixed Central and Obstructive Sleep Apnea, Mixed Sleep Apnea, Mixed Sleep Apneas, Pauses in breathing while sleeping, SDB, Sleep Apnea Syndromes, Sleep Apnea, Mixed, Sleep Apnea, Mixed Central and Obstructive, Sleep Apneas, Mixed, Sleep Hypopnea, Sleep Hypopneas, Sleep apnoea, sleep apnea, sleep apneas, sleep disordered breathing; Open Targets
Disease Ontology: DOID:0050847; Disease Ontology
MeSH: D012891; MeSH
NCI Thesaurus: C148023; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 29 drugs, from FDA; Open Targets

Drugs29

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SOLRIAMFETOL HYDROCHLORIDE	CHEMBL4297212	Small molecule	Approval	FDA	1	0	0	Drugs and targets
AMINO ACIDS	CHEMBL1201498		Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
IBUPROFEN	CHEMBL521	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MORPHINE	CHEMBL70	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RAMELTEON	CHEMBL1218	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MEDROXYPROGESTERONE ACETATE	CHEMBL717	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
MELATONIN	CHEMBL45	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
ACETAZOLAMIDE	CHEMBL20	Small molecule	Phase 2	ClinicalTrials.gov	8	8	8	Drugs and targets
(E/Z)-S-600918	CHEMBL5084939		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 29

See all 29 drugs

Targets49

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA2A	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Phase 2	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Phase 2	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Phase 2	https://conductscience.org/library/genes/152	Drugs and targets
ADRA1A	Adrenergic receptor	3	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist	Early phase 1	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	3	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist	Early phase 1	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	3	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist	Early phase 1	https://conductscience.org/library/genes/146	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	2	Serotonin 2a (5-HT2a) receptor antagonist	Phase 2	https://conductscience.org/library/genes/3356	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	2	Serotonin 2c (5-HT2c) receptor antagonist	Phase 2	https://conductscience.org/library/genes/3358	Drugs and targets
MTNR1A	Melatonin receptor	2	Melatonin receptor agonist	Phase 3	https://conductscience.org/library/genes/4543	Drugs and targets
MTNR1B	Melatonin receptor	2	Melatonin receptor agonist	Phase 3	https://conductscience.org/library/genes/4544	Drugs and targets

1 to 10 of 49

See all 49 targets

Trials25

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00001723	Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases	Phase 2	200	2012-12-18	Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity, Sleep Apnea Syndrome	ORLISTAT	Its record names the disease	ClinicalTrials.gov
NCT02552303	The Treatment of Insomnia Comorbid With Sleep Disordered Breathing Using Armodafinil and/or Cognitive Behavioral Therapy for Insomnia	Not applicable	39	2017-07-31	Sleep Apnea, Insomnia	ARMODAFINIL	Its record names the disease	ClinicalTrials.gov
NCT01184118	DREAM: Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea Manifestations?	Not applicable	36	2016-06-13	Lung Disease	FLUTICASONE PROPIONATE	Its record names the disease	ClinicalTrials.gov
NCT00816829	Effect of Fenofibrate on Sleep Apnea Syndrome	Phase 2	34	2009-07-07	Dyslipidemia, Sleep Apnea Syndrome, Overweight, Obesity	FENOFIBRATE	Its record names the disease	ClinicalTrials.gov
NCT01832532	A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks	Phase 1/2	34	2020-10-20	Sleep Apnea, Sleep Disordered Breathing	LIRAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT01377987	Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients	Not applicable	29	2018-06-13	Heart Failures	ACETAZOLAMIDE	Its record names the disease	ClinicalTrials.gov
NCT01048242	Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)	Phase 3	27	2017-05-03	Insomnia, Obstructive Sleep Apnea	RAMELTEON	Its record names the disease	ClinicalTrials.gov
NCT04799782	Role of Mirtazapine in Ameliorating Sleep Disordered Breathing	Phase 2	18	2021-04-20	Spinal Cord Injuries, Sleep Disordered Breathing	MIRTAZAPINE	Its record names the disease	ClinicalTrials.gov
NCT01045122	Sedation in Patients at Risk for Upper Airway Collapse	Not applicable	15	2015-04-27	Obstructive Sleep Apnea	DEXMEDETOMIDINE, PROPOFOL	Its record names the disease	ClinicalTrials.gov
NCT02458469	Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI	Phase 2	15	2020-04-09	Spinal Cord Injury, Sleep Disordered Breathing	BUSPIRONE, TRAZODONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 25

See all 25 trials

Comparisons in its trials9

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Orlistat vs Placebo: serious adverse events	0 of 100	2 of 100	200	NCT00001723	Trial comparisons
Acetazolamide vs Placebo: deaths from any cause	0 of 28	0 of 28	56	NCT01377987	Trial comparisons
Acetazolamide vs Placebo: serious adverse events	0 of 28	0 of 28	56	NCT01377987	Trial comparisons
Treatment Group- Liraglutide vs Control Group: deaths from any cause	0 of 18	0 of 9	27	NCT01832532	Trial comparisons
Treatment Group- Liraglutide vs Control Group: serious adverse events	0 of 18	0 of 9	27	NCT01832532	Trial comparisons
Mirtazapine vs Placebo: deaths from any cause	0 of 13	0 of 12	25	NCT04799782	Trial comparisons
Mirtazapine vs Placebo: serious adverse events	0 of 13	1 of 12	25	NCT04799782	Trial comparisons
Propofol vs Dexmedetomidine: serious adverse events	0 of 11	0 of 11	22	NCT01045122	Trial comparisons
Ramelteon vs Sugar Pill: serious adverse events	0 of 8	0 of 13	21	NCT01048242	Trial comparisons

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
15112907	RESULT	1	PubMed
12126214	RESULT	1	PubMed
12105286	RESULT	1	PubMed
41349930	DERIVED	1	PubMed
33059389	DERIVED	1	PubMed
29718281	DERIVED	1	PubMed
29510792	DERIVED	1	PubMed
26210388	DERIVED	1	PubMed
25624387	DERIVED	1	PubMed
24991933	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005296

GET https://conductscience.org/api/diseases/v1/MONDO_0005296/drugs?page=2

API reference For AI assistants